Relapsed or refractory nongastric marginal zone B-cell lymphoma

Multicenter retrospective analysis of 92 cases

Sung Yong Oh, Won Seog Kim, Seok Jin Kim, Jinseok Kim, Sung Hyun Kim, Dae Ho Lee, Jong Ho Won, In Gyu Hwang, Min Kyoung Kim, Soon Il Lee, Jong Gwang Kim, Deok Hwan Yang, Hye Jin Kang, Chul Won Choi, Jinny Park, Young Jin Choi, Hyo Jung Kim, Jung Hye Kwon, Cheolwon Suh, Hyo Jin Kim

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Over its long survival duration, marginal zone B-cell lymphoma (MZL) routinely involves frequent relapses. In this study, we conducted a retrospective analysis to identify the clinical features and outcomes of relapsed or refractory MZL. From 1995 to 2008, a total of 92 patients with relapsed MZL were retrospectively analyzed. The median age of our subjects was 53.5 years (range: 23-82 years). The most common primary sites of involvement were the orbit and ocular adnexa (28.3%) followed by the lymph node and lymphatic organs (23.9%), and multiple mucosa-associated lymphoid tissue (MALT) sites (13.0%). The median time to relapse from initial diagnosis was 25.5 months. Of the 53 patients with Stage I or II at diagnosis, 42 patients (79.2%) evidenced locoregional recurrence. Among these locoregional relapsed patients, 27 patients achieved CR (54.1%) or PR (18.9%). In addition to the 39 patients initially in advanced Stage III or IV, a total of 50 patients were in advanced stage at relapse. Among those patients with advanced stage at relapse, 44 patients were treated. The overall response rate was 54.5% (24 patients), with 18 CRs and 6 PRs. The median time to progression (TTP) was 34.1 months (95% CI: 11.3-56.9 months) and the estimated 5-year overall survival (OS) was 84.3%. The majority of them was controlled well with salvage treatment, and could achieve prolonged survival. However, patients' refractory to initial therapy and advanced relapse evidenced shorter TTP and OS. Thus, we need to consider more aggressive treatment in cases of refractory MZL or advanced relapsed MZL.

Original languageEnglish
Pages (from-to)826-829
Number of pages4
JournalAmerican Journal of Hematology
Volume84
Issue number12
DOIs
Publication statusPublished - 2009 Dec 1

Fingerprint

Marginal Zone B-Cell Lymphoma
Recurrence
Survival
Salvage Therapy
Lymphoid Tissue
Orbit
Mucous Membrane
Lymph Nodes

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Oh, Sung Yong ; Kim, Won Seog ; Kim, Seok Jin ; Kim, Jinseok ; Kim, Sung Hyun ; Lee, Dae Ho ; Won, Jong Ho ; Hwang, In Gyu ; Kim, Min Kyoung ; Lee, Soon Il ; Kim, Jong Gwang ; Yang, Deok Hwan ; Kang, Hye Jin ; Choi, Chul Won ; Park, Jinny ; Choi, Young Jin ; Kim, Hyo Jung ; Kwon, Jung Hye ; Suh, Cheolwon ; Kim, Hyo Jin. / Relapsed or refractory nongastric marginal zone B-cell lymphoma : Multicenter retrospective analysis of 92 cases. In: American Journal of Hematology. 2009 ; Vol. 84, No. 12. pp. 826-829.
@article{430a0bc573ac43f7998ce97cbfe516b9,
title = "Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases",
abstract = "Over its long survival duration, marginal zone B-cell lymphoma (MZL) routinely involves frequent relapses. In this study, we conducted a retrospective analysis to identify the clinical features and outcomes of relapsed or refractory MZL. From 1995 to 2008, a total of 92 patients with relapsed MZL were retrospectively analyzed. The median age of our subjects was 53.5 years (range: 23-82 years). The most common primary sites of involvement were the orbit and ocular adnexa (28.3{\%}) followed by the lymph node and lymphatic organs (23.9{\%}), and multiple mucosa-associated lymphoid tissue (MALT) sites (13.0{\%}). The median time to relapse from initial diagnosis was 25.5 months. Of the 53 patients with Stage I or II at diagnosis, 42 patients (79.2{\%}) evidenced locoregional recurrence. Among these locoregional relapsed patients, 27 patients achieved CR (54.1{\%}) or PR (18.9{\%}). In addition to the 39 patients initially in advanced Stage III or IV, a total of 50 patients were in advanced stage at relapse. Among those patients with advanced stage at relapse, 44 patients were treated. The overall response rate was 54.5{\%} (24 patients), with 18 CRs and 6 PRs. The median time to progression (TTP) was 34.1 months (95{\%} CI: 11.3-56.9 months) and the estimated 5-year overall survival (OS) was 84.3{\%}. The majority of them was controlled well with salvage treatment, and could achieve prolonged survival. However, patients' refractory to initial therapy and advanced relapse evidenced shorter TTP and OS. Thus, we need to consider more aggressive treatment in cases of refractory MZL or advanced relapsed MZL.",
author = "Oh, {Sung Yong} and Kim, {Won Seog} and Kim, {Seok Jin} and Jinseok Kim and Kim, {Sung Hyun} and Lee, {Dae Ho} and Won, {Jong Ho} and Hwang, {In Gyu} and Kim, {Min Kyoung} and Lee, {Soon Il} and Kim, {Jong Gwang} and Yang, {Deok Hwan} and Kang, {Hye Jin} and Choi, {Chul Won} and Jinny Park and Choi, {Young Jin} and Kim, {Hyo Jung} and Kwon, {Jung Hye} and Cheolwon Suh and Kim, {Hyo Jin}",
year = "2009",
month = "12",
day = "1",
doi = "10.1002/ajh.21557",
language = "English",
volume = "84",
pages = "826--829",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "12",

}

Oh, SY, Kim, WS, Kim, SJ, Kim, J, Kim, SH, Lee, DH, Won, JH, Hwang, IG, Kim, MK, Lee, SI, Kim, JG, Yang, DH, Kang, HJ, Choi, CW, Park, J, Choi, YJ, Kim, HJ, Kwon, JH, Suh, C & Kim, HJ 2009, 'Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases', American Journal of Hematology, vol. 84, no. 12, pp. 826-829. https://doi.org/10.1002/ajh.21557

Relapsed or refractory nongastric marginal zone B-cell lymphoma : Multicenter retrospective analysis of 92 cases. / Oh, Sung Yong; Kim, Won Seog; Kim, Seok Jin; Kim, Jinseok; Kim, Sung Hyun; Lee, Dae Ho; Won, Jong Ho; Hwang, In Gyu; Kim, Min Kyoung; Lee, Soon Il; Kim, Jong Gwang; Yang, Deok Hwan; Kang, Hye Jin; Choi, Chul Won; Park, Jinny; Choi, Young Jin; Kim, Hyo Jung; Kwon, Jung Hye; Suh, Cheolwon; Kim, Hyo Jin.

In: American Journal of Hematology, Vol. 84, No. 12, 01.12.2009, p. 826-829.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Relapsed or refractory nongastric marginal zone B-cell lymphoma

T2 - Multicenter retrospective analysis of 92 cases

AU - Oh, Sung Yong

AU - Kim, Won Seog

AU - Kim, Seok Jin

AU - Kim, Jinseok

AU - Kim, Sung Hyun

AU - Lee, Dae Ho

AU - Won, Jong Ho

AU - Hwang, In Gyu

AU - Kim, Min Kyoung

AU - Lee, Soon Il

AU - Kim, Jong Gwang

AU - Yang, Deok Hwan

AU - Kang, Hye Jin

AU - Choi, Chul Won

AU - Park, Jinny

AU - Choi, Young Jin

AU - Kim, Hyo Jung

AU - Kwon, Jung Hye

AU - Suh, Cheolwon

AU - Kim, Hyo Jin

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Over its long survival duration, marginal zone B-cell lymphoma (MZL) routinely involves frequent relapses. In this study, we conducted a retrospective analysis to identify the clinical features and outcomes of relapsed or refractory MZL. From 1995 to 2008, a total of 92 patients with relapsed MZL were retrospectively analyzed. The median age of our subjects was 53.5 years (range: 23-82 years). The most common primary sites of involvement were the orbit and ocular adnexa (28.3%) followed by the lymph node and lymphatic organs (23.9%), and multiple mucosa-associated lymphoid tissue (MALT) sites (13.0%). The median time to relapse from initial diagnosis was 25.5 months. Of the 53 patients with Stage I or II at diagnosis, 42 patients (79.2%) evidenced locoregional recurrence. Among these locoregional relapsed patients, 27 patients achieved CR (54.1%) or PR (18.9%). In addition to the 39 patients initially in advanced Stage III or IV, a total of 50 patients were in advanced stage at relapse. Among those patients with advanced stage at relapse, 44 patients were treated. The overall response rate was 54.5% (24 patients), with 18 CRs and 6 PRs. The median time to progression (TTP) was 34.1 months (95% CI: 11.3-56.9 months) and the estimated 5-year overall survival (OS) was 84.3%. The majority of them was controlled well with salvage treatment, and could achieve prolonged survival. However, patients' refractory to initial therapy and advanced relapse evidenced shorter TTP and OS. Thus, we need to consider more aggressive treatment in cases of refractory MZL or advanced relapsed MZL.

AB - Over its long survival duration, marginal zone B-cell lymphoma (MZL) routinely involves frequent relapses. In this study, we conducted a retrospective analysis to identify the clinical features and outcomes of relapsed or refractory MZL. From 1995 to 2008, a total of 92 patients with relapsed MZL were retrospectively analyzed. The median age of our subjects was 53.5 years (range: 23-82 years). The most common primary sites of involvement were the orbit and ocular adnexa (28.3%) followed by the lymph node and lymphatic organs (23.9%), and multiple mucosa-associated lymphoid tissue (MALT) sites (13.0%). The median time to relapse from initial diagnosis was 25.5 months. Of the 53 patients with Stage I or II at diagnosis, 42 patients (79.2%) evidenced locoregional recurrence. Among these locoregional relapsed patients, 27 patients achieved CR (54.1%) or PR (18.9%). In addition to the 39 patients initially in advanced Stage III or IV, a total of 50 patients were in advanced stage at relapse. Among those patients with advanced stage at relapse, 44 patients were treated. The overall response rate was 54.5% (24 patients), with 18 CRs and 6 PRs. The median time to progression (TTP) was 34.1 months (95% CI: 11.3-56.9 months) and the estimated 5-year overall survival (OS) was 84.3%. The majority of them was controlled well with salvage treatment, and could achieve prolonged survival. However, patients' refractory to initial therapy and advanced relapse evidenced shorter TTP and OS. Thus, we need to consider more aggressive treatment in cases of refractory MZL or advanced relapsed MZL.

UR - http://www.scopus.com/inward/record.url?scp=73349124477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349124477&partnerID=8YFLogxK

U2 - 10.1002/ajh.21557

DO - 10.1002/ajh.21557

M3 - Article

VL - 84

SP - 826

EP - 829

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 12

ER -